- Home
- MEDP vs SNN Comparison
MEDP vs SNN Comparison
Compare MEDP & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- SNN
- Stock Information
- Founded
- MEDP 1992
- SNN 1856
- Country
- MEDP United States
- SNN United Kingdom
- Employees
- MEDP N/A
- SNN N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- SNN Industrial Specialties
- Sector
- MEDP Health Care
- SNN Health Care
- Exchange
- MEDP Nasdaq
- SNN Nasdaq
- Market Cap
- MEDP 13.4B
- SNN 15.2B
- IPO Year
- MEDP 2016
- SNN 1999
- Fundamental
- Price
- MEDP $585.14
- SNN $32.50
- Analyst Decision
- MEDP Hold
- SNN Hold
- Analyst Count
- MEDP 12
- SNN 4
- Target Price
- MEDP $465.18
- SNN $32.83
- AVG Volume (30 Days)
- MEDP 324.1K
- SNN 593.1K
- Earning Date
- MEDP 10-22-2025
- SNN 10-30-2025
- Dividend Yield
- MEDP N/A
- SNN 2.25%
- EPS Growth
- MEDP 25.36
- SNN 59.91
- EPS
- MEDP 14.32
- SNN 0.56
- Revenue
- MEDP $2,358,373,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- MEDP $21.48
- SNN $7.85
- Revenue Next Year
- MEDP $11.90
- SNN $5.43
- P/E Ratio
- MEDP $40.91
- SNN $58.35
- Revenue Growth
- MEDP 13.88
- SNN 5.35
- 52 Week Low
- MEDP $250.05
- SNN $23.69
- 52 Week High
- MEDP $625.00
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- MEDP 57.97
- SNN 31.31
- Support Level
- MEDP $573.07
- SNN $33.05
- Resistance Level
- MEDP $609.13
- SNN $33.66
- Average True Range (ATR)
- MEDP 16.64
- SNN 0.51
- MACD
- MEDP -3.57
- SNN -0.32
- Stochastic Oscillator
- MEDP 38.72
- SNN 12.92
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.